BlackRock Amends Castle Biosciences Stake to 9.2%
Ticker: CSTL · Form: SC 13G/A · Filed: 2024-01-25T00:00:00.000Z
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a big chunk of Castle Biosciences, showing continued institutional interest.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in Castle Biosciences Inc. As of December 31, 2023, BlackRock beneficially owned 2,427,337 shares of Castle Biosciences' Common Stock, representing 9.2% of the company. This is an amendment (Amendment No. 2) to a previous filing, indicating a change in their holdings. This matters to investors because BlackRock is a major institutional investor, and their significant stake and any changes in it can signal confidence or concern about Castle Biosciences' future performance.
Why It Matters
BlackRock's substantial 9.2% ownership in Castle Biosciences Inc. signals strong institutional confidence, which can positively influence other investors' perceptions and potentially the stock price.
Risk Assessment
Risk Level: low — This filing indicates a stable, significant institutional ownership, which generally reduces volatility and provides a level of confidence.
Analyst Insight
Investors should note BlackRock's continued significant stake as a sign of institutional confidence, but also monitor future filings for any substantial changes in their position, which could signal a shift in their outlook on Castle Biosciences Inc.
Key Numbers
- 2,427,337 — Shares Owned (BlackRock's beneficial ownership in Castle Biosciences Inc. as of December 31, 2023.)
- 9.2% — Ownership Percentage (The percentage of Castle Biosciences Inc.'s Common Stock owned by BlackRock Inc.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Castle Biosciences Inc. (company) — the subject company in which shares are held
- 2,427,337 (dollar_amount) — number of shares beneficially owned by BlackRock
- 9.2% (dollar_amount) — percentage of class owned by BlackRock
- December 31, 2023 (date) — date of the event requiring the filing
- January 25, 2024 (date) — date the SC 13G/A was filed
Forward-Looking Statements
- BlackRock will maintain a significant stake in Castle Biosciences Inc. for the foreseeable future. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What is the purpose of an SC 13G/A filing?
An SC 13G/A is an amendment to a Schedule 13G, which is filed by institutional investors like BlackRock Inc. to report beneficial ownership of 5% or more of a company's stock, indicating a change in their holdings from a previous filing.
Which company is the subject of this SC 13G/A filing?
The subject company of this filing is CASTLE BIOSCIENCES INC, as stated in the 'Name of Issuer' section of the Schedule 13G.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as identified in the 'Names of reporting persons' section of the filing.
What was BlackRock's beneficial ownership percentage in Castle Biosciences Inc. as of the event date?
As of December 31, 2023, BlackRock Inc. beneficially owned 9.2% of the Common Stock of Castle Biosciences Inc.
What is the CUSIP number for Castle Biosciences Inc. Common Stock?
The CUSIP number for Castle Biosciences Inc. Common Stock is 14843C105, as listed in the filing.
From the Filing
EDGAR Filing Documents for 0001086364-24-003353 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] SEC Accession No. 0001086364-24-003353 Filing Date 2024-01-25 Accepted 2024-01-25 13:48:56 Documents 1 Document Format Files Seq Description Document Type Size 1 us14843c1053_012524.txt SC 13G/A 11790 Complete submission text file 0001086364-24-003353.txt 13656 Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 212-810-5300 BlackRock Inc. (Filed by) CIK : 0001364742 (see all company filings) EIN. : 320174431 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance) Mailing Address 505 S FRIENDSWOOD DRIVE SUITE 401 FRIENDSWOOD TX 77546 Business Address 505 S FRIENDSWOOD DRIVE SUITE 401 FRIENDSWOOD TX 77546 866-788-9007 CASTLE BIOSCIENCES INC (Subject) CIK : 0001447362 (see all company filings) EIN. : 770701774 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A | Act: 34 | File No.: 005-91094 | Film No.: 24561126 SIC : 8071 Services-Medical Laboratories (CF Office: 08 Industrial Applications and Services)